Lars Rebien Sorensen is back as chairman of Novo Nordisk A/S following a shareholder meeting that exposed the depth of rivalry between the Danish drugmaker and US arch nemesis Pfizer Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback